B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Completed · Phase 3

Conditions studied: HIV Infection, Hepatitis B

In brief

The purpose of this study was to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations of people living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are naïve to HBV vaccination.

Key facts

Study ID
NCT04193189
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
638
Starts
2020-12-14
Expected to finish
2024-08-13
Last updated by the study team
2025-07-20

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.